Clinical Nurse Specialists

Rakovina Therapeutics Announces Q3 2025 Financial Results and Corporate Update

1 week ago talkbio0Tagged AI-powered, ATR Inhibitor, Clinical Nurse Specialists, Conferences, corporate milestones, development expenses, Ditiocarb, Drug Discovery, Eligibility Determination, financial results, Investments, NanoPalm joint-venture, net loss, Penetration, Q3, Rakovina, research

Rakovina Therapeutics; Q3 2025; financial results; net loss; research and development expenses; AI-powered drug discovery; ATR inhibitor; CNS penetration; corporate milestones; NanoPalm joint-venture; investment conference; DTC eligibility

Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib in TKI Pre-treated Advanced ROS1-positive NSCLC

3 weeks ago talkbio0Tagged acceptance, ARROS-1 trial, Breakthrough Therapy, Clinical Nurse Specialists, Identifier, New Drug Application, Non-Small Cell Lung Carcinoma, Nuvalent, orphan drug designation, PDUFA, Penetration, pre-treated, Protein-tyrosine kinase inhibitor, ROS1-positive, United States Food and Drug Administration, zidesamtinib

Nuvalent; zidesamtinib; FDA acceptance; New Drug Application (NDA); ROS1-positive NSCLC; tyrosine kinase inhibitor (TKI) pre-treated; ARROS-1 trial; PDUFA date; CNS penetration; breakthrough therapy designation; orphan drug designation

LB Pharmaceuticals Files for $228M IPO to Fund Phase III Schizophrenia Drug

3 months ago talkbio0Tagged Alzheimer 's psychosis, amisulpride, Clinical Nurse Specialists, Depression, Bipolar, IPO, LB-102, Nasdaq, Phase 3 Clinical Trials, Pounds, Schizophrenia, United States Food and Drug Administration

LB Pharmaceuticals; IPO; Phase III trial; schizophrenia; LB-102; biotech; CNS therapeutics; bipolar depression; Alzheimer’s psychosis; amisulpride; FDA; Nasdaq